The Latest Cardiac and Vascular News
Positive 12-month results from the VOLT-AF IDE Study presented at the AF Symposium and simultaneously published in JACC: Clinical Electrophysiology, reinforce the Volt™ Pulsed Field Ablation (PFA) System’s industry-leading success rate for treating AFib1 New data from the FOCALFLEX CE Mark trial demonstrate the safety and efficacy of the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, to […]
Positive 12-month results from the VOLT-AF IDE Study presented at the AF Symposium and simultaneously published in JACC: Clinical Electrophysiology, reinforce the Volt™ Pulsed Field Ablation (PFA) System’s industry-leading success rate for treating AFib1 New data from the FOCALFLEX CE…
Abbott’s TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, is designed with dual-energy to treat atrial fibrillation patients with the most challenging cases It can deliver both radiofrequency energy and pulsed field ablation (PFA) energy during procedures to target and treat an…
Collaboration pairs AtaCor’s investigational extravascular ICD lead with Abbott’s investigational extravascular ICD system to deliver potentially life-saving therapies AtaCor plans to initiate a pivotal Investigational Device Exemption (IDE) clinical trial in 2026 to evaluate the investigational extravascular implantable cardioverter defibrillator (EV-ICD) system This initiative furthers Abbott’s leadership in advancing next-generation […]
Abbott’s Volt™ PFA System, the latest generation of cardiac ablation technology, is designed for people battling heart rhythm disorders such as atrial fibrillation (AFib) Pulsed field ablation – or PFA – is a minimally invasive procedure that uses high-energy electrical pulses in targeted…
New data reveal a 78% reduction in cardiovascular disease-related hospitalizations for people living with Type 1 diabetes with prior severe low blood sugar episodes.1 This significant decrease is linked to the use of Libre biowearable technology compared to traditional blood glucose…
Long-term data from the Volt CE Mark Study show strong results out to 12 months in patients receiving pulsed field ablation (PFA) therapy with the Volt™ PFA System The 12-month results of the Volt CE Mark Study confirm the long-term safety and efficacy of the Volt PFA System The data were…
TRILUMINATE™ Pivotal data presented at the American College of Cardiology’s Annual Scientific Session (ACC.25) and simultaneously published in Circulation show the Abbott TriClip system reduces heart failure hospitalizations The latest results highlight significant improvements in…
Abbott’s Volt™ PFA System is designed to provide a new therapy option for people battling heart rhythm disorders such as atrial fibrillation Pulsed field ablation – or PFA – uses high energy electrical pulses for ablation procedures that may offer benefits to targeting and treating tissue…
Coronary Artery Disease (CAD) is the most common heart disease and most frequent cause of death in the U.S., with over 20 million adults affected by this condition Abbott’s investigational Coronary Intravascular Lithotripsy (IVL) System offers a new potential treatment by using sound…
